All News
Less Organ Damage with Remission in SLE
A cohort study of SLE patients shows that remission and low disease activity (LDA) are associated with less damage accrual over time.
Read Article
Utility of Repeat ENA Antibody Testing
Repeat serologic testing is not uncommon, but is it warranted? A retrospective study shows that repeated testing for autoantibodies to extractable nuclear antigens (ENA) rarely changes the result or adds a new diagnosis.
Read Article
The Great Unknowns (8.5.2022)
Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.
Read Article
ACR Updated Guideline on Vaccinations for Rheumatic Patients
The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).
Read Article
Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus
Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. When administered to patients with cutaneous lupus erythematosus (CLE) was shown reducing disease activity in CLE patients.
Read Article
Approach to ILD in Myositis Syndromes
Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.
Read Article
Rheumatic Causes for Fever of Unknown Origin
Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.
Read Article
Nintedinib’s Durable Efficacy in Systemic Sclerosis
Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.
Read Article
Links:
Links:
Links:
Cogan's syndr is a rare autoimmune dz, all ages (20-30s) & races (whites) w/ ocular (interstitial keratitis) & audio/vestibular Sx (deafness, vertigo). Less: HA, fever, myalgias, aortitis, heart. No Dx test; 1/3 have another systemic dz. Rx: steroids https://t.co/e3sstsxO5R https://t.co/CQ3UfBqO0e
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
